Experimental drugs for bipolar psychosis

Drugs under early investigation for the treatment of bipolar disorder

(2015) George Konstantakopoulos et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Epigenetic approaches for bipolar disorder drug discovery

(2014) Jacob Peedicayil   Expert Opinion on Drug Discovery

Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force

(2013) Benicio N Frey et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1 and with increased CSF KYNA level and reduced KMO expression

(2013) C Lavebratt et al.   MOLECULAR PSYCHIATRY

A safe lithium mimetic for bipolar disorder

(2013) Nisha Singh et al.   Nature Communications

GABAergic neuroactive steroids: a new frontier in bipolar disorders?

(2012) Mauro Giovanni Carta et al.   Behavioral and Brain Functions

Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder

(2012) Sara K Olsson et al.   BIPOLAR DISORDERS

Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice

(2012) Jayashri Kulkarni et al.   BMC Psychiatry

Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance

(2012) Matteo Martino et al.   Current Neuropharmacology

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

(2012) Konstantinos N. Fountoulakis et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

(2012) Robert K McNamara et al.   Expert Review of Neurotherapeutics

Putative neuroprotective agents in neuropsychiatric disorders

(2012) Seetal Dodd et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors

(2012) Michael Maes et al.   INFLAMMOPHARMACOLOGY

Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells

(2011) Quan Wang et al.   CELL RESEARCH

Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?

(2011) Michele Fornaro et al.   EXPERT OPINION ON PHARMACOTHERAPY

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

(2011) Marc De Hert et al.   Nature Reviews Endocrinology

Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression

(2011) Brian Leonard et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

New Drugs for Bipolar Disorder

(2011) Marsal Sanches et al.   Current Psychiatry Reports

Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?

(2011) Konstantinos N Fountoulakis et al.   Annals of General Psychiatry

Animal models of neuropsychiatric disorders

(2010) Eric J Nestler et al.   NATURE NEUROSCIENCE

Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors

(2010) M. Berk et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder

(2010) I. J. Torres et al.   PSYCHOLOGICAL MEDICINE

Signaling pathways in schizophrenia: emerging targets and therapeutic strategies

(2010) Caline S. Karam et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Medicating mood with maintenance in mind: bipolar depression pharmacotherapy

(2009) Gin S Malhi et al.   BIPOLAR DISORDERS

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

(2009) M. De Hert et al.   EUROPEAN PSYCHIATRY

Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology

(2009) GM Goodwin et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study

(2009) Jayendra K. Patel et al.   SCHIZOPHRENIA RESEARCH

Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics

(2008) Christoph U Correll et al.   BIPOLAR DISORDERS

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

(2008) S Leucht et al.   MOLECULAR PSYCHIATRY